This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by BRESSION, D. Articles by PEILLON, F. Search for Related Content PubMed PubMed Citation Articles by BRESSION, D. Articles by PEILLON, F.

Dopaminergic Receptors in Human Prolactin-Secreting Adenomas: A Quantitative Study^*

INSERM FRA 33, Physiopathologie de l’Hypophyse 75014 Paris, France
Service de Biochimie Médicale 75014 Paris, France
Laboratoire d'Histologie-Embryologie 75014 Paris, France
Faculté de Médecine Pitié-Salpêtriére, 75634 Paris Cedex 13; and Unite 109 de Neurobiologie, Centre Paul Broca de l’INSERM 75014 Paris, France

Address requests for reprints to: D. Bression, INSERM FRA 33, Faculte de Médecine Pitié-SalpêtriMére, 105 Boulevard de l'Hôpital, 75634 Paris Cedex 13, France.

Dopaminergic receptors were observed on the membranes of 26 human PRL-secreting adenomas. Two binding sites were found for [³H]domperidone, a selective dopamine antagonist, with a Kd₁ of 0.29 ± 0.06 nM and a Kd₂ of 4.19 ± 0.7 nM (n = 5). Bmax₁ and Bmax₂ (maximum numbers of binding sites, first and second sites, respectively) varied from one adenoma to another.

When considering Bmax₁, two different categories of PRL-secreting adenomas were distinguished, one with a concentration of receptor over 250 fmol/mg protein and others with lower concentrations of receptor (<250 fmol/mg protein). In the latter, when considering the volume of the tumor, a higher plasma PRL level was found.

Two binding sites for [³H]domperidone also were found in the normal human hypophysis with Kd values similar to those of the adenomas (0.18 ± 0.04 and 3.95 ± 0.35 nM). The same number of binding sites was observed in normal pituitaries and in PRL-secreting adenomas. However, when considering the density of PRL-secreting cells in the two different tissues (prolactinomas contain 2 or 3 times more PRL-secreting cells than human pituitary tissue), one may suspect a defect in the dopaminergic inhibiting control in PRL-secreting adenomas.

^* This work was supported by the Institut National de la Santé etde la Recherche Médicale (CRAT 49.77.81) and the Centre National de la Recherche Scientifique (E.R.A. 484).

Received March 20, 1980.

This article has been cited by other articles:

				W. W de Herder, A. E M Reijs, R. A Feelders, M. O van Aken, E. P Krenning, A.-J. van der Lely, and D. J Kwekkeboom Diagnostic imaging of dopamine receptors in pituitary adenomas Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S53 - S56. [Abstract] [Full Text] [PDF]

				A. Colao, M. Filippella, R. Pivonello, C. Di Somma, A. Faggiano, and G. Lombardi Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S57 - S63. [Abstract] [Full Text] [PDF]

				M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao Advances in the Treatment of Prolactinomas Endocr. Rev., August 1, 2006; 27(5): 485 - 534. [Abstract] [Full Text] [PDF]

				R. Pivonello, D. Ferone, W. W. de Herder, J. M. Kros, M. L. Del Basso De Caro, M. Arvigo, L. Annunziato, G. Lombardi, A. Colao, L. J. Hofland, et al. Dopamine Receptor Expression and Function in Corticotroph Pituitary Tumors J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2452 - 2462. [Abstract] [Full Text] [PDF]

				R. Pivonello, C. Matrone, M. Filippella, L. M. Cavallo, C. Di Somma, P. Cappabianca, A. Colao, L. Annunziato, and G. Lombardi Dopamine Receptor Expression and Function in Clinically Nonfunctioning Pituitary Tumors: Comparison with the Effectiveness of Cabergoline Treatment J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1674 - 1683. [Abstract] [Full Text] [PDF]

				J. Trouillas, P. Chevallier, C. Remy, F. Rajas, R. Cohen, A. Calle, E. L. Hooghe-Peters, and B. Rousset Differential Actions of the Dopamine Agonist Bromocriptine on Growth of SMtTW Tumors Exhibiting a Prolactin and/or a Somatotroph Cell Phenotype: Relation to Dopamine D2 Receptor Expression Endocrinology, January 1, 1999; 140(1): 13 - 21. [Abstract] [Full Text]